Harmony Biosciences Announces Executive Appointments and Departures

TL;DR

Harmony Bio shuffles execs: Dayno is new CMO, Simpson is CCO, Smith departs.

AI Summary

Harmony Biosciences Holdings, Inc. announced on June 27, 2024, a series of executive changes. Dr. Jeffrey M. Dayno has been appointed Chief Medical Officer, and Ms. Jennifer L. T. Simpson has been appointed Chief Commercial Officer. The company also announced the departure of Dr. Robert E. Smith as Chief Medical Officer, effective June 27, 2024.

Why It Matters

These executive changes could signal a shift in the company's strategic direction or operational focus, potentially impacting its drug development and commercialization efforts.

Risk Assessment

Risk Level: medium — Executive changes can introduce uncertainty regarding future strategy and leadership stability.

Key Players & Entities

• Harmony Biosciences Holdings, Inc. (company) — Registrant
• Dr. Jeffrey M. Dayno (person) — Appointed Chief Medical Officer
• Ms. Jennifer L. T. Simpson (person) — Appointed Chief Commercial Officer
• Dr. Robert E. Smith (person) — Departed Chief Medical Officer
• June 27, 2024 (date) — Effective date of changes

FAQ

From the Filing

0001558370-24-009642.txt : 20240701 0001558370-24-009642.hdr.sgml : 20240701 20240701161515 ACCESSION NUMBER: 0001558370-24-009642 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240627 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240701 DATE AS OF CHANGE: 20240701 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Harmony Biosciences Holdings, Inc. CENTRAL INDEX KEY: 0001802665 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822279923 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39450 FILM NUMBER: 241090780 BUSINESS ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 BUSINESS PHONE: (484) 539-9800 MAIL ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 8-K 1 hrmy-20240627x8k.htm 8-K 0001802665 false 0001802665 2024-06-27 2024-06-27 ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ​ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ​ Date of report (Date of earliest event reported): June 27, 2024 ​ HARMONY BIOSCIENCES HOLDINGS, INC . (Exact name of registrant as specified in its charter) ​ ​ ​ ​ Delaware 001-39450 82-2279923 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) ​ 630 W. Germantown Pike , Suite 215 Plymouth Meeting , PA 19462 (Address of principal executive offices) (Zip Code) ( 484 ) 539-9800 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report.) ​ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ​ ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ​ ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ​ ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Securities registered pursuant to Section 12(b) of the Act: ​ ​ ​ ​ ​ ​      Trading      Name of each exchange Title of each class ​ Symbol(s) ​ on which registered Common Stock, $0.00001 par value per share ​ HRMY ​ The Nasdaq Global Market ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ​ Emerging growth company ☐ ​ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ ​ ​ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. ​ ​ On June 27, 2024, Jack Bech Nielsen notified the Board of Directors (the “Board”) of Harmony Biosciences Holdings, Inc. (the “Company”) that he is resigning from the Board effective immediately, due to h